ArticleApplied biochemistry and biotechnology2026
Acacetin Alleviates Cigarette Smoke-Induced Chronic Obstructive Pulmonary Disease in Mice by Inhibiting NLRP3 Inflammasome-Mediated Pyroptosis.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pyroptosis in chronic obstructive pulmonary disease: Beyond the canonical NLRP3/Caspase-1/GSDMD pathway.Immunologic research · 2026Review
- Efficacy and mechanisms of andrographolide derivative in acute exacerbations of chronic obstructive pulmonary disease: a meta-analysis, network pharmacology, molecular docking, andFrontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acacetin, a flavonoid, exhibits potent anti-inflammatory activity. However, its therapeutic potential against cigarette smoke (CS)-induced chronic obstructive pulmonary disease (COPD) remains unclear. Therefore, we aimed to investigate the protective role of acacetin in CS-induced COPD. A COPD mouse model was established by CS exposure. Mice were intragastrically administered with acacetin (20, 40, or 80 mg/kg). BEAS-2B cells were cultured with cigarette smoke extract (CSE) to explore the molecular mechanisms of acacetin. The effects of acacetin on lung function were evaluated using pulmonary function tests and histological staining. Its anti-inflammatory effects were assessed by immunohistochemistry, immunofluorescence, Western blotting, quantitative real-time PCR (qRT-PCR), and enzyme-linked immunosorbent assay. Acacetin ameliorated CS-induced lung function impairment, airway remodeling, and collagen deposition in mouse lungs. The levels of inflammatory factors decreased after acacetin treatment. Acacetin significantly reduced pyroptosis by inhibiting NLR family pyrin domain containing 3 (NLRP3) inflammasome-related protein expression in tissues and cells. Excessive lactate dehydrogenase (LDH) release induced by CSE was reversed by acacetin. Furthermore, NLRP3 overexpression in BEAS-2B cells reversed the suppressive effects of acacetin on inflammatory factor levels. Acacetin significantly alleviated CS-induced pyroptosis by modulating the NLRP3 inflammasome.
Indexed as
Identifiers
41258604What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.